Investigating Epstein-Barr Virus Associated Conjunctivitis
NCT06689397 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 5
Last updated 2024-11-14
Summary
Conjunctivitis means inflammation of the conjunctiva, the thin transparent layer over the white of the eye and under the eyelids. Acute conjunctivitis caused by infection is the most common condition seen in ophthalmic emergency departments, accounting for up to 10% of cases. It is responsible for 41% of eye-related general practice consultations. A diagnosis is usually made on the patient's symptoms and signs, despite this being less reliable than laboratory testing. When a cause is found, it is usually a common cold virus called adenovirus, that gets better with time and does not require treatment.
Through investigating cases of conjunctivitis at Moorfields, it has been discovered that in addition to adenovirus, Epstein Barr virus (EBV) is sometimes detected in conjunctival swabs from individuals with conjunctivitis. EBV is a very common viral infection that 95% of adults have experienced. EBV infection mostly passes unnoticed but when symptoms do occur, they include a sore throat, high temperature, swollen glands and tiredness, often called glandular fever or infectious mononucleosis. Conjunctivitis can also occur. EBV remains in the body after infection and rarely causes further problems. The virus can become active again occasionally, which is known as reactivation.
Reactivation usually passes unnoticed but sometimes is associated with recurrence of symptoms. It is possible that reactivation may cause conjunctivitis. It is not certain, which is will be observed as a part of this study, as it might be the cause of some of the conjunctivitis seen.
Through a collaboration with University College London (UCL), the aim is to gain further insight into infectious conjunctivitis, particularly in relation to EBV. This will be done by taking a swab of the conjunctiva, a single blood test and a tiny (1-2mm) tissue sample from the inner eyelid. Improved knowledge will allow the research team to develop better guidance and treatment for patients with conjunctivitis.
Conditions
- Conjunctivitis
- EBV Infection
Sponsors & Collaborators
-
Moorfields Eye Hospital NHS Foundation Trust
lead OTHER
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-10-09
- Primary Completion
- 2025-06-02
- Completion
- 2025-06-02
Countries
- United Kingdom
Study Locations
More Related Trials
-
ADenoVirus Initiative Study in Epidemiology in UK
NCT02112773 ·Status: COMPLETED
-
OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis
NCT03856645 ·Status: UNKNOWN ·Phase: PHASE2
-
A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
NCT02082899 ·Status: COMPLETED ·Phase: PHASE2
-
Ocular Surface Dry Eye Microbiome
NCT02306668 ·Status: UNKNOWN
-
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
NCT00223951 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
NCT00798577 ·Status: COMPLETED ·Phase: PHASE4
-
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
NCT00759148 ·Status: COMPLETED ·Phase: PHASE3
-
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
NCT00931957 ·Status: UNKNOWN ·Phase: NA
-
Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19)
NCT04456556 ·Status: COMPLETED
-
A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
NCT01220258 ·Status: TERMINATED ·Phase: PHASE2
-
Tofacitinib for Inflammatory Eye Disease
NCT03580343 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
NCT00105469 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
NCT05579730 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319 ·Status: COMPLETED ·Phase: PHASE3
-
Non-invasive Diagnostics of Microbial Keratitis
NCT06364878 ·Status: RECRUITING
-
Systemic Pharmacokinetics of BOL-303224-A
NCT00407589 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
NCT00629941 ·Status: COMPLETED ·Phase: PHASE4
-
Endogenous Endophthalmitis in the Inpatient Setting
NCT01323868 ·Status: COMPLETED
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
NCT00105534 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life In Patients With Allergic Conjunctivitis In Treatment With Sublingual Allergen Immunotherapy In A Referral Ophthalmological Hospital
NCT07149298 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
NCT00244543 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
NCT02079649 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
NCT01877694 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Search in Conjunctival Cells
NCT04364594 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
NCT02432807 ·Status: COMPLETED ·Phase: PHASE3